These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1207 related items for PubMed ID: 20043812

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias.
    Herbert MK, Aerts MB, Kuiperij HB, Claassen JAHR, Spies PE, Esselink RAJ, Bloem BR, Verbeek MM.
    Alzheimers Dement; 2014 Jul; 10(4):448-455.e2. PubMed ID: 24239248
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
    Sauvée M, DidierLaurent G, Latarche C, Escanyé MC, Olivier JL, Malaplate-Armand C.
    J Alzheimers Dis; 2014 Jul; 41(2):377-86. PubMed ID: 24614902
    [Abstract] [Full Text] [Related]

  • 5. Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies.
    van Steenoven I, van der Flier WM, Scheltens P, Teunissen CE, Lemstra AW.
    Alzheimers Res Ther; 2019 Oct 10; 11(1):83. PubMed ID: 31601267
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Plasma and cerebrospinal fluid ABeta42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care setting.
    Kokkinou M, Beishon LC, Smailagic N, Noel-Storr AH, Hyde C, Ukoumunne O, Worrall RE, Hayen A, Desai M, Ashok AH, Paul EJ, Georgopoulou A, Casoli T, Quinn TJ, Ritchie CW.
    Cochrane Database Syst Rev; 2021 Feb 10; 2(2):CD010945. PubMed ID: 33566374
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias.
    de Souza LC, Lamari F, Belliard S, Jardel C, Houillier C, De Paz R, Dubois B, Sarazin M.
    J Neurol Neurosurg Psychiatry; 2011 Mar 10; 82(3):240-6. PubMed ID: 20802215
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. CSF tau, Aβ42, and MHPG differentiate dementia with Lewy bodies from Alzheimer's disease.
    Aerts MB, Esselink RA, Claassen JA, Abdo WF, Bloem BR, Verbeek MM.
    J Alzheimers Dis; 2011 Mar 10; 27(2):377-84. PubMed ID: 21841257
    [Abstract] [Full Text] [Related]

  • 12. Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias.
    Bibl M, Mollenhauer B, Lewczuk P, Esselmann H, Wolf S, Trenkwalder C, Otto M, Stiens G, Rüther E, Kornhuber J, Wiltfang J.
    Mol Psychiatry; 2007 Jul 10; 12(7):671-80. PubMed ID: 17339876
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Novel fluid biomarkers to differentiate frontotemporal dementia and dementia with Lewy bodies from Alzheimer's disease: A systematic review.
    Chaudhry A, Houlden H, Rizig M.
    J Neurol Sci; 2020 Aug 15; 415():116886. PubMed ID: 32428759
    [Abstract] [Full Text] [Related]

  • 15. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.
    Luo X, Hou L, Shi H, Zhong X, Zhang Y, Zheng D, Tan Y, Hu G, Mu N, Chan J, Chen X, Fang Y, Wu F, He H, Ning Y.
    J Neurochem; 2013 Dec 15; 127(5):681-90. PubMed ID: 23800322
    [Abstract] [Full Text] [Related]

  • 16. CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia.
    Bibl M, Mollenhauer B, Esselmann H, Lewczuk P, Klafki HW, Sparbier K, Smirnov A, Cepek L, Trenkwalder C, Rüther E, Kornhuber J, Otto M, Wiltfang J.
    Brain; 2006 May 15; 129(Pt 5):1177-87. PubMed ID: 16600985
    [Abstract] [Full Text] [Related]

  • 17. Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies.
    Mollenhauer B, Bibl M, Wiltfang J, Steinacker P, Ciesielczyk B, Neubert K, Trenkwalder C, Otto M.
    Clin Chem Lab Med; 2006 May 15; 44(2):192-5. PubMed ID: 16475906
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
    Caminiti SP, Ballarini T, Sala A, Cerami C, Presotto L, Santangelo R, Fallanca F, Vanoli EG, Gianolli L, Iannaccone S, Magnani G, Perani D, BIOMARKAPD Project.
    Neuroimage Clin; 2018 May 15; 18():167-177. PubMed ID: 29387532
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 61.